Real-life Efficacy of Omalizumab After 9 Years of Follow-up

• DOI: 10.4168/aair.2017.9.4.368
• Publication Date: 2017-05-12T07:34:21Z
• Authors: Francesco Menzella; Carla Galeone; Debora Formisano; Claudia Castagnetti; Patrizia Ruggiero; Anna Simonazzi; Luigi Zucchi
• Keywords: Omalizumab

Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients asthma will typically require chronic treatment, although due the limited amount data available there are still some concerns about safety efficacy long-term therapy omalizumab. Herein, an extension a previous 4-year study, we report disease-related outcomes 8 persistent allergic who have been followed for total 9 years real-life setting. Both quality life (QoL) (evaluated using Juniper Asthma-Related QoL Questionnaire [AQLQ]) forced expiratory volume 1 second (FEV1) showed sustained improvement at years. The median values AQLQ FEV1 4 were 5.5 82.0% compared 5.9 85.5%, respectively, years, which all significantly increased from baseline. After mean annual number exacerbations was 0.63 5 There also appeared be trend toward use lower dose ICS longer follow-up times. no continued omalizumab, asthma-related hospitalizations or emergency department visits documented over last present analysis longest reported clinical Long-term maintenance omalizumab up associated benefits reducing symptoms, exacerbations, medication burden without any concerns.